Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis

Abstract Confirming the patient benefit of progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) has become increasingly challenging due to the improved outcomes brought by novel therapies. In parallel, the U.S. Food and Drug Administration recommends condu...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoshi Hirano, Keisuke Hanada, Hideki Maeda
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-05053-6
Tags: Add Tag
No Tags, Be the first to tag this record!